drugset / Trial / NCT00035022
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
Timeline
- Start
- 2001-08
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | forodesine | Small molecule | — | Intravenous |